PF-07976016
Sources
registry, as of 2026-02-06Stale
https://clinicaltrials.gov/study/NCT06717425
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity. Overall status COMPLETED. Phases PHASE2. Lead sponsor Pfizer. Enrollment 263. Conditions Obesity. The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-07976016) to those of participants w
ClinicalTrials.gov NCT06717425 protocol and results modules
registry, as of 2025-08-07Stale
https://clinicaltrials.gov/study/NCT06910839
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity. Overall status TERMINATED. Phases PHASE1. Lead sponsor Pfizer. Enrollment 21. Conditions Overweight; Obesity. The purpose of this study is to see how two study medicines, PF-07976016 and danuglipron, taken together affect the level of each other in the blood of participants who have overweight or obesity. The total number of weeks of the study is up to approximately 22 weeks (5.5 months
ClinicalTrials.gov NCT06910839 protocol and results modules